Market research
22UA.F BioNTech SE
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 21B
- P/E ratio
- Not available
- Analyst target
- 334.89
- Dividend yield
- Not available
- Beta
- 1.29
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US09075V1026
- Market cap
- 21B
- P/E ratio
- Not available
- Analyst target
- 334.89
- Dividend yield
- Not available
- Beta
- 1.29
About
About BioNTech SE
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 22UA.F discussion.
5 years, 5 months ago
BioNTech SE is currently in a long term uptrend where the price is trading 57.6% above its 200 day moving average.
From a valuation standpoint, the stock is 96.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 49.5.
BioNTech SE's total revenue rose by 1134.3% to $345M since the same quarter in the previous year.
Its net income has increased by 730.2% to $367M since the same quarter in the previous year.
Finally, its free cash flow grew by 406.1% to $224M since the same quarter in the previous year.
Based on the above factors, BioNTech SE gets an overall score of 5/5.